WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas.
WT1 diffusely stains most ovarian serous carcinomas; reactivity of uterine papillary serous carcinomas has not been evaluated. We studied WT1 expression in 13 International Federation of Gynecology and Obstetrics stage 1 and 5 stage 3 or 4 uterine papillary serous carcinomas without ovarian metastases and compared their reactivity with the WT1 staining of 30 ovarian serous carcinomas. WT1 reactivity was evaluated with the C19 and 6F-H2 antibody clones. All 18 uterine papillary serous carcinomas were nonreactive for WT1. The nonovarian metastases of the 5 high-stage uterine papillary serous carcinomas also were nonreactive for WT1. In contrast, 29 (97%) of 30 ovarian serous carcinomas were reactive for WT1. WT1 reactivity in an unknown primary serous carcinoma would suggest it is from a nonuterine site. The mechanisms underlying these findings are unknown. They raise the possibility of genetic differences between the 2 morphologically similar neoplasms.
Goldstein
Neal S
NS
Department of Anatomic Pathology, William Beaumont Hospital, Royal Oak, MI 48073, USA.
Uzieblo
Alison
A
D002467:Cell Nucleus / Q000737:chemistry; D003536:Cystadenocarcinoma / Q000737:chemistry*; D018283:Cystadenocarcinoma, Papillary / Q000737:chemistry*; D003593:Cytoplasm / Q000737:chemistry; D004727:Endothelium / Q000737:chemistry; D005260:Female; D015870:Gene Expression; D006801:Humans; D009362:Neoplasm Metastasis; D010051:Ovarian Neoplasms / Q000737:chemistry*; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D014594:Uterine Neoplasms / Q000737:chemistry*; D025721:WT1 Proteins / Q000032:analysis* / Q000235:genetics
D016159:Tumor Suppressor Protein p53; D025721:WT1 Proteins